Manufacturer
21 recalls in our database name GlaxoSmithKline, LLC. as the manufacturing or recalling firm.
Of the 21 recalls from GlaxoSmithKline, LLC. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 11 (52%) are Severe.
Which agencies issued them
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
GlaxoSmithKline recalls TIVICAY cartons nationwide with incorrect expiration date on packaging. The carton label shows May 2026, but the correct expiration on the bottle is April 2025.
GlaxoSmithKline is recalling 67,508 Anoro Ellipta inhalers nationwide because coarse particle mass failed release testing and was found out of specification. No illnesses have been reported.
GlaxoSmithKline is recalling 328 bottles of Tivicay (dolutegravir) tablets nationwide due to incorrect expiration date labeling. The label shows January 2027 but the correct expiration date is September 2026.
GlaxoSmithKline is recalling specific lots of Ventolin HFA inhalers because some units have out-of-specification leak rates.
GlaxoSmithKline is recalling 593,088 Ventolin inhalers because some units have out-of-specification leak rates, potentially affecting drug delivery.
GlaxoSmithKline is recalling Bactroban Nasal ointment tubes due to penicillin cross-contamination. The recall covers 153,119 units distributed nationwide and in Puerto Rico.
GlaxoSmithKline is recalling Bactroban Cream (Mupirocin Calcium Cream 2%) due to penicillin cross-contamination. The recall covers 7,480 tubes distributed nationwide and in Puerto Rico.
GlaxoSmithKline is recalling 18,000 tubes of Bactroban Ointment because of penicillin cross-contamination. The affected product is distributed nationwide and in Puerto Rico.
GlaxoSmithKline is recalling Bactroban Cream (Mupirocin Calcium Cream 2%) due to penicillin cross contamination. The recall affects 28,131 tubes distributed nationwide and in Puerto Rico.
GlaxoSmithKline is recalling Ventolin HFA inhalers because some may not deliver the full 200 actuations labeled on the canister.
GlaxoSmithKline is recalling Bactroban Nasal Ointment due to penicillin cross-contamination and foreign substances found during manufacturing.
GlaxoSmithKline is recalling Bactroban Cream (mupirocin calcium) 2% because the product was contaminated with penicillin and foreign substances during manufacturing.
GlaxoSmithKline is recalling Bactroban Ointment due to penicillin cross-contamination and foreign substances found during manufacturing.
GlaxoSmithKline is recalling Mupirocin Calcium Cream, 2%, because the product was contaminated with penicillin and foreign substances during manufacturing.
GlaxoSmithKline is recalling 10,469 Imitrex STATdose Systems because some syringes may have needles protruding through the shield, compromising sterility.
GlaxoSmithKline is recalling 9,743 cartridges of Sumatriptan Succinate Injection because some may have needles protruding through the shield, compromising sterility.
GlaxoSmithKline is recalling Biotene Moisturizing Mouth Spray because the label lists sorbitol, but the product does not contain it.
GlaxoSmithKline is recalling TUMS Ultra Assorted Berries 1000mg chewable tablets because they may contain foreign TUMS 750mg tablets.
GlaxoSmithKline is recalling specific lots of Arranon (nelarabine) Injection because drug-related impurities may exceed specification limits.
GlaxoSmithKline is recalling specific lots of Advair HFA inhalers because they failed to meet particle size distribution specifications.
GlaxoSmithKline is recalling 18,676 units of Advair HFA inhalers because they failed to meet particle size distribution specifications.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
GlaxoSmithKline
company in Tokyo, Japan
Source: Wikidata (Q43896200), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.